PL3938040T3 - Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśni - Google Patents
Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśniInfo
- Publication number
- PL3938040T3 PL3938040T3 PL20717988.8T PL20717988T PL3938040T3 PL 3938040 T3 PL3938040 T3 PL 3938040T3 PL 20717988 T PL20717988 T PL 20717988T PL 3938040 T3 PL3938040 T3 PL 3938040T3
- Authority
- PL
- Poland
- Prior art keywords
- anticoagulants
- vitamin
- combination
- treating muscle
- muscle soreness
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817037P | 2019-03-12 | 2019-03-12 | |
| PCT/NO2020/050066 WO2020185092A2 (en) | 2019-03-12 | 2020-03-11 | Use of vitamin k in combination with anticoagulants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3938040T3 true PL3938040T3 (pl) | 2025-07-14 |
Family
ID=70228770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20717988.8T PL3938040T3 (pl) | 2019-03-12 | 2020-03-11 | Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśni |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200289521A1 (pl) |
| EP (1) | EP3938040B1 (pl) |
| JP (2) | JP7615044B2 (pl) |
| CN (2) | CN117414431A (pl) |
| AU (3) | AU2020236308B2 (pl) |
| BR (1) | BR112021018002A2 (pl) |
| CA (2) | CA3255246A1 (pl) |
| CL (3) | CL2021002363A1 (pl) |
| IL (2) | IL314746A (pl) |
| MX (3) | MX2021010977A (pl) |
| PL (1) | PL3938040T3 (pl) |
| WO (1) | WO2020185092A2 (pl) |
| ZA (2) | ZA202106359B (pl) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ583069A (en) * | 2007-07-24 | 2012-06-29 | Viridis Biopharma Pvt Ltd | Treatments using vitamin k analogues and derivatives |
| US8211947B2 (en) * | 2008-01-28 | 2012-07-03 | Guillermo Selman-Housein Sosa | Composition and method for treating and preventing musculoskeletal and connective tissue disorders |
| WO2010103545A2 (en) * | 2009-03-12 | 2010-09-16 | Viridis Biopharma Pvt Ltd, | Method of use of vitamin k as energy enhancer in diverse disease states |
| EP2886129A1 (en) * | 2013-12-20 | 2015-06-24 | VitaK B.V. | Prevention and counteraction of diet-induced thrombosis risk |
| EP3801477A4 (en) * | 2018-06-08 | 2022-02-23 | Epizon Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF TISSUE CALCIFICATION |
-
2020
- 2020-03-11 CN CN202311402823.2A patent/CN117414431A/zh active Pending
- 2020-03-11 WO PCT/NO2020/050066 patent/WO2020185092A2/en not_active Ceased
- 2020-03-11 US US16/815,855 patent/US20200289521A1/en active Pending
- 2020-03-11 PL PL20717988.8T patent/PL3938040T3/pl unknown
- 2020-03-11 AU AU2020236308A patent/AU2020236308B2/en active Active
- 2020-03-11 MX MX2021010977A patent/MX2021010977A/es unknown
- 2020-03-11 CA CA3255246A patent/CA3255246A1/en active Pending
- 2020-03-11 CA CA3132245A patent/CA3132245A1/en active Pending
- 2020-03-11 JP JP2021554988A patent/JP7615044B2/ja active Active
- 2020-03-11 US US17/437,087 patent/US20220160652A1/en active Pending
- 2020-03-11 EP EP20717988.8A patent/EP3938040B1/en active Active
- 2020-03-11 CN CN202080020385.1A patent/CN113557032A/zh active Pending
- 2020-03-11 BR BR112021018002A patent/BR112021018002A2/pt unknown
- 2020-03-11 IL IL314746A patent/IL314746A/en unknown
-
2021
- 2021-08-31 ZA ZA2021/06359A patent/ZA202106359B/en unknown
- 2021-09-09 CL CL2021002363A patent/CL2021002363A1/es unknown
- 2021-09-09 IL IL286245A patent/IL286245A/en unknown
- 2021-09-10 MX MX2024007166A patent/MX2024007166A/es unknown
- 2021-09-10 MX MX2024007164A patent/MX2024007164A/es unknown
-
2022
- 2022-08-23 ZA ZA2022/09447A patent/ZA202209447B/en unknown
-
2023
- 2023-12-19 CL CL2023003790A patent/CL2023003790A1/es unknown
-
2024
- 2024-02-02 JP JP2024014647A patent/JP2024050759A/ja active Pending
- 2024-06-11 CL CL2024001729A patent/CL2024001729A1/es unknown
- 2024-08-30 AU AU2024216503A patent/AU2024216503B2/en active Active
- 2024-08-30 AU AU2024216508A patent/AU2024216508B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3938040B1 (en) | 2025-05-21 |
| CN113557032A (zh) | 2021-10-26 |
| CL2024001729A1 (es) | 2024-10-18 |
| AU2024216503B2 (en) | 2025-10-30 |
| US20220160652A1 (en) | 2022-05-26 |
| ZA202209447B (en) | 2024-05-30 |
| CN117414431A (zh) | 2024-01-19 |
| BR112021018002A2 (pt) | 2021-11-16 |
| CA3255246A1 (en) | 2025-05-28 |
| EP3938040A2 (en) | 2022-01-19 |
| US20200289521A1 (en) | 2020-09-17 |
| WO2020185092A3 (en) | 2020-11-12 |
| NZ781054A (en) | 2025-05-02 |
| CL2021002363A1 (es) | 2022-06-10 |
| EP3938040C0 (en) | 2025-05-21 |
| MX2024007166A (es) | 2024-06-26 |
| ZA202106359B (en) | 2023-08-30 |
| MX2021010977A (es) | 2021-12-10 |
| CL2023003790A1 (es) | 2024-07-26 |
| AU2024216508B2 (en) | 2025-10-30 |
| JP7615044B2 (ja) | 2025-01-16 |
| AU2020236308A1 (en) | 2021-11-04 |
| IL286245A (en) | 2021-10-31 |
| JP2022524619A (ja) | 2022-05-09 |
| WO2020185092A2 (en) | 2020-09-17 |
| AU2024216508A1 (en) | 2024-09-19 |
| IL314746A (en) | 2024-10-01 |
| AU2020236308B2 (en) | 2024-10-10 |
| MX2024007164A (es) | 2024-06-26 |
| CA3132245A1 (en) | 2020-09-17 |
| JP2024050759A (ja) | 2024-04-10 |
| AU2024216503A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3882250T3 (pl) | Amino-pirolopirymidynon tetrahydropiranylu do stosowania w leczeniu zaburzeń mediowanych przez btk | |
| IL272596A (en) | Pridopidine for use in the treatment of ALS | |
| IL255780A (en) | Therapeutic combinations and methods for treating neoplasia | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| LT4119569T (lt) | Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje | |
| ZA201900343B (en) | Self-contained treatment unit for haemodialysis treatments | |
| IL284053A (en) | New compounds and their use in therapy | |
| IL256135A (en) | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias | |
| IL273470A (en) | Semaglutide in medical treatment | |
| GB201503967D0 (en) | Biocompatible implants for use in tendon therapy | |
| EP3151932A4 (en) | Exercise device for blood circulation and metabolism in the knee | |
| PT3283064T (pt) | Derivados úteis para o tratamento da atrofia muscular | |
| SMT202200221T1 (it) | Medicinale per l'uso nel trattamento della gotta | |
| GB201821147D0 (en) | Mirna for use in therapy | |
| GB2592803B (en) | Compounds for use in preventing or treating athlete overtraining | |
| HUE045185T2 (hu) | Új terápiás vegyület és terápiában történõ alkalmazása | |
| ZA201907017B (en) | Combination therapy for use in treating retroviral infection | |
| PL3938040T3 (pl) | Witamina K2 w kombinacji z antykoagulantami do stosowania w leczeniu bolesności mięśni | |
| GB2539742B (en) | Therapeutic treatment methods, and apparatus for use therein | |
| GB201615844D0 (en) | Agents for use in therapy | |
| GB2510477B (en) | Formulations for use in the treatment of chronic fatigue and associated conditions, etc | |
| IL268265B (en) | 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment | |
| GB201702652D0 (en) | Delta-theraphotoxin-Ac1 for use in treating diabetes | |
| GB201512260D0 (en) | Improvements in or relating to beauty, health, or therapeutic treatments | |
| GB2553684B (en) | Ethynylxanthines, preparation and use for cancer treatment |